Nom du produit:tert-butyl 4-(prop-2-yn-1-yloxy)piperidine-1-carboxylate
IUPAC Name:tert-butyl 4-(prop-2-yn-1-yloxy)piperidine-1-carboxylate
- CAS：1219827-56-1
- Formule moléculaire：C13H21NO3
- Pureté：95%+
- Numéro de catalogue：CM1046429
- Poids moléculaire：239.32
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:1219827-56-1
- Formule moléculaire:C13H21NO3
- Point de fusion:-
- Code SMILES:CC(C)(C)OC(=O)N1CCC(CC1)OCC#C
- Densité:
- Numéro de catalogue:CM1046429
- Poids moléculaire:239.32
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Piperidines
- Piperidine is an azacycloalkane that is cyclohexane in which one of the carbons is replaced by a nitrogen. Although piperidine is a common organic compound, it is an immensely important class of compounds medicinally: the piperidine ring is the most common heterocyclic subunit among FDA approved drugs.
- Piperidine,Piperidine Price
- if you want to know the latest news about piperidine and piperidine price, please come to our website and get a quote for free.
Column Infos
- KT-474
- Kymera announced that the first patient has been dosed in the randomized Phase 2 clinical trial in hidradenitis suppurativa (HS) evaluating KT-474 (SAR444656). The Phase 2 study will evaluate the efficacy, safety, pharmacokinetics, and biological effects of KT-474 compared with placebo in adult patients with moderate to severe HS. Kymera's partner Sanofi is conducting the Phase 2 study in HS, and has initiated a second randomized Phase 2 trial in AD. Under the terms of the collaboration, dosing of the first patient in the HS trial generated a milestone payment of $40 million. KT-474 is an oral IRAK4 degrader, in development for the treatment of IL-1R/TLR-driven complex inflammatory diseases where there is an opportunity to significantly advance the standard of care, including HS and AD. Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immune-oncology fields, is conducting the Phase 2 studies.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Recherche 
+86 21 5895 0110 
